OQROGet OQRO Pro
Insider trade

Johnson & Johnson (JNJ)CFO sold ~$2.98M

Joseph J Wolk, CFO at Johnson & Johnson, sold ~$2.98M of Johnson & Johnson shares.

~$2.98M
Approx. value · 17K sh @ $176.91
14K
Holds after · shares reported
Traded
Aug 15, 2025
Filed
Aug 18, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 15, 2023CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Aug 7, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  3. Sep 26, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  4. Oct 29, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  5. Mar 19, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  6. May 12, 2025CongressDisclosed sale of JNJ — reported range $50,001 - $100,000
  7. Jun 10, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  8. Jun 12, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  9. Jun 16, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  10. Jun 17, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  11. Jun 24, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  12. Jul 17, 2025InsiderOfficer sold ~$3.13M of JNJ shares in the open market
  13. Jul 31, 2025CongressDisclosed partial sale of JNJ — reported range $15,001 - $50,000
  14. Aug 4, 2025Congress · 1 personMembers of Congress: 2 purchases
  15. Aug 14, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  16. Aug 15, 2025 · this disclosureInsiderCFO sold ~$2.98M of JNJ shares in the open market

What came next

  1. Aug 19, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  2. Aug 22, 2025InsiderCEO sold ~$22.5M of JNJ shares in the open market
  3. Sep 4, 2025Insider · 4 days before an 8-KOfficer sold ~$10M of JNJ shares in the open market
  4. Sep 8, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 8, 2025, Johnson & Johnson (the Company) announced that John Morikis was elected to the Board of Directors. The Board has determined that Mr. Morikis satisfies the applicable independence requirements of the NYSE Listed Company Manual.”
  5. Sep 23, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  6. Sep 26, 2025FDAFDA drug approval: Tremfya
  7. Sep 26, 2025FDAFDA drug approval: Tremfya
  8. Sep 26, 2025FDARecall: LOW PROF LCKNG SCREW, F/IM NAIL 5.0MM / L, 42MM / XL25/ STER. Product Code: 04.045.342TS. Used in RFN-ADVANCEDTM Retrograde Femoral Nailing (RFNA) System and t…
  9. Sep 26, 2025FDARecall: LOW PROF LCKNG SCREW, F/IM NAIL 5.0MM / L, 46MM / XL25/ STER. Product Code: 04.045.346TS. Used in RFN-ADVANCEDTM Retrograde Femoral Nailing (RFNA) System and t…
  10. Oct 1, 2025FDARecall: Automated Impella Controller (AIC), used for left heart support blood pump, labeled as the following with corresponding Product Codes: 1. Impella Controller, P…
  11. Oct 8, 2025FDAFDA device clearance: 14Fr Low Profile Introducer Kit
  12. Oct 9, 2025Federal contract · $19K obligatedDepartment of Veterans Affairs awarded Johnson & Johnson: $19K obligated to date
  13. Oct 10, 2025Congress · 1 personMembers of Congress: 2 sales
  14. Oct 14, 2025Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  15. Oct 16, 2025Federal contract · $384K obligatedDepartment of Defense awarded Johnson & Johnson: $384K obligated to date
  16. Oct 17, 2025InsiderOfficer sold ~$4.19M of JNJ shares in the open market
  17. Oct 18, 2025FDARecall: MONARCH Bronchoscope. Model Number: MBR-000211-B
  18. Oct 21, 2025FDAFDA device clearance: TriALTIS™ Spine System
  19. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  20. Oct 31, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 15 insider filings (SEC Form 4 or Form 144), 8 Congress trade reports, 167 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

Other recent filings by Joseph J Wolk, Exec VP, CFO

The full history of Joseph J Wolk, Exec VP, CFO is on the profile page.

How this filing works

Other disclosures at Johnson & Johnson

Everything OQRO holds on this company is on its JNJ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data